Evonetix announced today that it closed a $30 million Series B funding round as it develops technology for enabling gene synthesis on a chip.
The Cambridge, U.K.-based synthetic biology company said the funding round, led by new investor Foresite Capital, is slated to fund the company through to the introduction of its desktop DNA platform, according to a news release. Existing investors Draper Espirit, DCVC, The Morningside Group, Providence Investment Company, Cambridge Consultants, Rising Tide Fund and Civilization Ventures also participated in the financing.
Get the full story at our sister site, Drug Discovery & Development